Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...
A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...
A sponge-like implant in mice has helped guide a treatment that slowed or stopped a degenerative condition similar to ...
Understanding the behavior of tiny droplets in our cells could aid the search for new treatments. A team of Leiden ...
Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...
US-based biotech Abcuro has raised $200m to advance the development of its monoclonal antibody ulviprubart in the rare muscle disease called inclusion body myositis ... Abcuro’s candidate works by ...
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback